03D53F2A-5003-48D3-80CD-9C9BBCEBD59E
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.467
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.427
- HEDGEHOG_SIGNALING+0.373
- TNFA_SIGNALING_VIA_NFKB+0.313
- HEME_METABOLISM+0.272
- APICAL_SURFACE+0.270
- UV_RESPONSE_DN+0.264
- INFLAMMATORY_RESPONSE+0.261
- UV_RESPONSE_UP+0.256
- PI3K_AKT_MTOR_SIGNALING+0.208
Top 10 suppressed
- E2F_TARGETS-0.406
- G2M_CHECKPOINT-0.396
- INTERFERON_ALPHA_RESPONSE-0.393
- INTERFERON_GAMMA_RESPONSE-0.282
- IL6_JAK_STAT3_SIGNALING-0.220
- MYC_TARGETS_V1-0.215
- NOTCH_SIGNALING-0.192
- WNT_BETA_CATENIN_SIGNALING-0.191
- CHOLESTEROL_HOMEOSTASIS-0.140
- MITOTIC_SPINDLE-0.101
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 776FDD5D-E929-47F0-AE37-81B7431DD6CC | — | — | 0.764 |
| 2 | SRR1489137 | GTEX | — | 0.759 |
| 3 | SRR1102055 | GTEX | — | 0.756 |
| 4 | SRR816770 | GTEX | — | 0.743 |
| 5 | 618FAB92-C578-4144-9BD0-AEE1AFBFA08E | — | — | 0.742 |
| 6 | C4100609-0651-40E1-997A-0059432736B3 | — | — | 0.733 |
| 7 | SRR817751 | GTEX | — | 0.729 |
| 8 | 093A32DA-49D0-4F4C-9000-4F47B4700F4E | — | — | 0.728 |
| 9 | 8F5717EC-3344-48CA-9B0C-FCDED8C0F955 | — | — | 0.728 |
| 10 | SRR810319 | GTEX | — | 0.726 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.467 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.427 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.373 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.313 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.272 | Temsirolimus | — uncovered |
| APICAL_SURFACE | 0.270 | Temsirolimus | — uncovered |
| UV_RESPONSE_DN | 0.264 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.261 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.256 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.208 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.175 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.168 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.150 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.104 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.101 | Inavolisib | — uncovered |
| APOPTOSIS | 0.087 | Idelalisib | — uncovered |
| MYOGENESIS | 0.077 | Inavolisib | — uncovered |
| HYPOXIA | 0.075 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.070 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.066 | Inavolisib | — uncovered |